Related Experiment Video
Updated: Jul 24, 2026
06:32
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Effect of recombinant human interleukin 2 in experimental murine coccidioidomycosis
1Department of Internal Medicine, School of Medicine, University of California, Davis, Medical Center, Sacramento 95817.
Diagnostic Microbiology and Infectious Disease
|February 1, 1988
Abstract:
The therapeutic effect of recombinant human interleukin 2 (rH IL-2) was assessed in experimental murine coccidioidomycosis by daily IV injection for 30 days of doses ranging decimally from 2.5 X 10(1) to 2.5 X 10(5) units. The treatment with rH IL-2 had neither adverse nor salutary effects.
